Biogen, Inc. Reports Third Quarter 2011 Results  
10/28/2011 7:40:00 AM

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

Third Quarter 2011 Highlights: •Third quarter revenues increased 11% to $1.3 billion, compared to the third quarter of 2010. TYSABRI® (natalizumab) revenues increased 26% year-over-year to $277 million while AVONEX® (interferon beta-1a) revenues increased 6% year-over-year to $682 million. RITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $266 million for the quarter, an increase of 3% versus prior year.